

June 21, 2021



## Poxel Announces Participation and Presentations at the EASL (European Association for the Study of the Liver) International Liver Congress™ 2021

LYON, France--(BUSINESS WIRE)-- [POXEL SA](#) (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH) today announced its participation at the European Association for the Study of the Liver (EASL) International Liver Congress™ which will be held from June 23-26, 2021.

Poxel will present:

- “Human proof-of-concept in non-alcoholic liver disease (NAFLD) patients with PXL770, a novel first-in-class direct AMP-kinase activator -- STAMP-NAFLD Phase 2a trial” [Abstract #427; oral presentation to be held by Pr. Kenneth Cusi; June 25 during the “NAFLD: therapy” session]
- “Target engagement and evidence of efficacy with PXL770, a novel direct AMP-Kinase activator, in a 4-week PK/PD trial in patients with NAFLD” [Poster; Abstract #159, Vlad Ratziu *et al*, available on June 23]

EASL is a medical association dedicated to pursuing excellence in liver research, to the clinical practice of liver disorders, and to providing education to all those interested in hepatology. To learn more about the event, please visit: <https://easl.eu/easl/>

### About Poxel SA

Poxel is a **dynamic biopharmaceutical company** that uses its extensive expertise in developing **innovative drugs for metabolic diseases**, with a focus on **type 2 diabetes** and **non-alcoholic steatohepatitis** (NASH), and selected rare inherited disorders including adrenoleukodystrophy. In its mid-to-late-stage pipeline, the Company is currently advancing three drug candidates; several earlier-stage opportunities are also underway. Imeglimin, Poxel’s first-in-class lead product, targets mitochondrial dysfunction. Poxel has a strategic partnership with Sumitomo Dainippon Pharma for Imeglimin in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries. A Japanese new drug application (J-NDA) is under review by the Pharmaceuticals and Medical Devices Agency (PMDA) to request approval for the manufacturing and marketing of Imeglimin for the treatment of type 2 diabetes. After successfully completing a Phase 2a proof-of-concept trial for the treatment of

NASH, which met its primary objectives, for **PXL770**, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, Poxel plans to initiate a Phase 2b program in the second half of 2021. PXL770 could also have the potential to treat additional metabolic diseases. **PXL065** (deuterium-stabilized R-pioglitazone) is in a streamlined Phase 2 trial for the treatment of NASH. Poxel also has additional earlier-stage programs from its AMPK activator and deuterated TZD platforms targeting chronic and rare metabolic diseases. The Company intends to generate further growth through strategic partnerships and pipeline development. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan. For more information, please visit: [www.poxelpharma.com](http://www.poxelpharma.com)

In the context of the COVID-19 outbreak, which was declared a pandemic by the World Health Organization (WHO) on March 12, 2020, the Company is regularly reviewing the impact of the outbreak on its business.

As of the date of this press release, and based on publicly available information, the Company has not identified the occurrence of any material negative effect on its business due to the COVID-19 pandemic that remains unresolved. However, the Company anticipates that the COVID-19 pandemic could have further material negative impact on its business operations. The worldwide impact of COVID-19 may notably affect the Company's internal organization and efficiency, particularly in countries where it operates and where confinement measures are implemented by the authorities. In addition, COVID-19 may impact market conditions and the Company's ability to seek additional funding or enter into partnerships. Particularly, delays in the supply of drug substance or drug products, in the initiation or the timing of results of preclinical and/or clinical trials, as well as delays linked to the responsiveness of regulatory authorities could occur, which could potentially have an impact on the Company's development programs and partnered programs. The Company will continue to actively monitor the situation.

All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20210621005302/en/>

## **Poxel SA**

Catherine David

Investor Relations & Communication Manager

[catherine.david@poxelpharma.com](mailto:catherine.david@poxelpharma.com)

+33 7 64 57 61 78

**Investor relations / Media - EU/US**

Trophic Communications

Stephanie May or Valeria Fisher

[poxel@trophic.eu](mailto:poxel@trophic.eu)

+49 171 185 56 82 or +49 175 804 1816

**Investor relations / Media - France**

NewCap

Emmanuel Huynh or Arthur Rouillé

[poxel@newcap.eu](mailto:poxel@newcap.eu)

+33 1 44 71 94 94

Source: Poxel SA